<DOC>
	<DOCNO>NCT02316197</DOCNO>
	<brief_summary>MSC2490484A investigational drug evaluate treatment subject advance solid tumor chronic lymphocytic leukemia ( CLL ) likely differs cancer repair damage DNA ( genetic material ) . This first-in-man Phase I study , mean first time study drug use human . The main purpose determine high dose cause unacceptable side effect . The second determine appropriate dose use future research subject cancer . Othergoals study learn drug 's safety side effect , affect tumor , body process drug .</brief_summary>
	<brief_title>Clinical Phase I Study Investigating MSC2490484A , Inhibitor DNA-dependent Protein Kinase , Advanced Solid Tumors Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This Phase I , first-in-human , open-label , dose escalation , dose expansion trial design explore safety , tolerability , PK PD profile , clinical activity MSC2490484A administer daily single agent subject advance solid tumor CLL likely alteration DNA repair mechanism . Dose Escalation : Subjects receive MSC2490484A continuously start dose 100 mg daily . Sequential treatment cohort receive ascend dos MSC2490484A daily twice daily ( determined appropriate Safety Monitoring Committee [ SMC ] ) follow standard `` 3+3 '' design . The SMC make dose escalation decision base review available safety , tolerability , Pharmacokinetic ( PK ) , Pharmacodynamic ( PD ) data . Once maximum tolerate dose ( MTD ) establish , Recommended Phase II Dose ( RP2D ) define SMC , either MTD level another dose level , depend available data safety , efficacy , PK , PD observe trial . The SMC may decide stop dose escalation time trial . Up 12 subject enrol RP2D/Optimal biologic dose ( OBD ) confirm safety tolerability explore PK PD profile MSC2490484A . Expansion cohort : Once subject evaluate RP2D , additional subject enrol 2 expansion cohort ( 20 evaluable subject per expansion cohort ) evaluate clinical efficacy tumor likely alteration DNA repair mechanism ( eg , CLL tumor type ) . Subjects evaluable efficacy receive least 1 dose study drug radiographic baseline . Subjects evaluable efficacy replace .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Advanced solid tumor likely alteration DNA repair mechanism , BRCA ATM pathway , CLL , standard surgical , radiation , systemic anticancer therapy available . Subjects CLL enrol 1 RP2D expansion cohort . Tumor accessible biopsy agree pretreatment tumor biopsy Measurable evaluable disease accordance RECIST v 1.1 solid tumor ChesonÂ´s criterion CLL Male female subject least 18 year age sign write informed consent . Other protocoldefined criterion could apply Eastern Cooperative Oncology Group performance status &gt; 1 Prior treatment chemotherapy , immunotherapy , hormonal therapy , exception luteinizing hormone release hormone ( LHRH ) analog , biologic therapy , anticancer therapy , investigational agent within 28 day first dose MSC2490484A ( 6 week nitrosoureas mitomycin C ) Extensive prior radiotherapy 30 % bone marrow reserve prior bone marrow/stem cell transplantation within 5 year study start . The extent previous radiotherapy bone marrow determine investigator . Receiving medication herbal supplement know potent inhibitor cytochrome P450 3A4 inducer cytochrome P450 3A4 . Not recovered toxicity due prior therapy baseline AE CTCAE Grade 1 less ( except alopecia ) Poor vital organ function define protocol Significant cardiac conduction abnormality define protocol Central nervous system metastases unless previously radiotherapy treat , stable computerize tomography ( CT ) scan least 3 month without evidence cerebral edema , requirement corticosteroids anticonvulsant Other protocoldefined criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DNA-PK Inhibitor</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>Chronic lymphocytic Leukemia</keyword>
	<keyword>Phase I , first-in-human</keyword>
	<keyword>dose escalation</keyword>
	<keyword>dose expansion</keyword>
	<keyword>safety profile</keyword>
	<keyword>tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>antitumor activity</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>M3814</keyword>
</DOC>